EGFR and non-small cell lung carcinoma: For patients with stage II-IIIA NSCLC (UICC/AJCC staging system, 7th ed) who received adjuvant platinum-based chemotherapy, without Epidermal Growth Factor Receptor (EGFR) mutation, adjuvant atezolizumab improved DFS (HR= 0·79; 0·64-0·96; p=0·020) for 16 cycles or 1 year.